Greeting from President and Chief Executive Officer

Shigeo Taniuchi President and Chief Executive Officer Photo

Through our global business activities, we aim to improve quality of life for patients around the world by harnessing the deep-rooted patient centric approach and its expertize and technical capabilities in ophthalmology, which we have built up over the 130 years of our company's history. This year, 2020, represents the final year of our current long-term strategic vision and three-year medium term plan. As CEO, my aim is to make steady progress in expanding our business globally, including participation in the US market, put into practice the next long-term strategic vision, and achieve further growth for the company as we aim to establish ourselves as a "Specialized Pharmaceutical Company with a Global Presence", as laid out in our management vision.

Currently, at least 2.2 billion people globally have visual disorders or have lost their sight. Patient numbers are expected to continue rising for reasons including the increasing numbers of elderly people and economic development in emerging economies, lending a greater importance to our roles and responsibilities. In addition to leveraging our company's advantages globally in the field of ophthalmology, we aim to take on board new skills and technologies as we move to achieve long-term growth in 2020 and beyond, contributing to the development of ophthalmological treatment in various countries and regions and to the greater happiness of people worldwide through improved health. We ask you all for your continued guidance and encouragement.

Shigeo Taniuchi President and Chief Executive Officer